Labs agree on brain tumor type with a DNA test, but not always on the extra details
Original title: Interlaboratory performance testing on EPIC v2.0 CNS tumor profiling demonstrates high reproducibility of tumor classification but reveals the need for harmonized copy number variation reporting.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This checks a lab test that doctors already use today to help name brain tumors.
The short version
A lab test that helps name a brain tumor gave the same answer at almost every lab, though some labs read part of the results differently.
What was studied. Slides from eight brain tumor samples were sent to 24 labs in 10 countries. Each lab ran the same DNA methylation test and reported the tumor class and the copy number changes it saw.
What they found. The labs produced very similar data. Eighteen of the 24 centers (75%) passed the test. Six centers did not pass. Two of them had technical problems that led to wrong answers on some cases. Four others named the tumor type correctly but disagreed about how to read important copy number changes.
What this means, and what it doesn't
What it could mean: If you have this test done, the part that names your tumor type is likely to be reliable. The extra part that looks at gains and losses of DNA can be read differently from lab to lab. Doctors read this test along with the rest of your results, not on its own.
What it doesn't mean: This is not a treatment and not a cure. It does not change what care you get or how well you will do. The study only checked how well labs perform a test that is already in use. It also does not mean any one lab got your result wrong.
Source: PubMed, July 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.